JP2017533250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533250A5 JP2017533250A5 JP2017525079A JP2017525079A JP2017533250A5 JP 2017533250 A5 JP2017533250 A5 JP 2017533250A5 JP 2017525079 A JP2017525079 A JP 2017525079A JP 2017525079 A JP2017525079 A JP 2017525079A JP 2017533250 A5 JP2017533250 A5 JP 2017533250A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- carbocyclyl
- optionally substituted
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *c1cc(C(Cl=*)=CN(*)C2=O)c2[n]1 Chemical compound *c1cc(C(Cl=*)=CN(*)C2=O)c2[n]1 0.000 description 34
- UQUHZULWYMQRSS-SNAWJCMRSA-N C/C=C/CN(C=C(C(N(CC1)CCC1N(C)C)=O)c1c2[nH]cc1)C2=O Chemical compound C/C=C/CN(C=C(C(N(CC1)CCC1N(C)C)=O)c1c2[nH]cc1)C2=O UQUHZULWYMQRSS-SNAWJCMRSA-N 0.000 description 1
- LUCLJGBDSYDVPO-UHFFFAOYSA-N C/S=C/C(N(CC1)CCC1C1=CC(F)=CC#CC1)=O Chemical compound C/S=C/C(N(CC1)CCC1C1=CC(F)=CC#CC1)=O LUCLJGBDSYDVPO-UHFFFAOYSA-N 0.000 description 1
- YYJHYDDYSZUMOR-UHFFFAOYSA-N CC(C)c(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CC(C)c(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O YYJHYDDYSZUMOR-UHFFFAOYSA-N 0.000 description 1
- HDZPZWTWOZYVDA-UHFFFAOYSA-N CC(C)c1cccc(N(CC2)CCC2N(C)C(C2=CN(C)C(C)c3c2cc[nH]3)=O)c1 Chemical compound CC(C)c1cccc(N(CC2)CCC2N(C)C(C2=CN(C)C(C)c3c2cc[nH]3)=O)c1 HDZPZWTWOZYVDA-UHFFFAOYSA-N 0.000 description 1
- LEMGAKAAUNGWHX-UHFFFAOYSA-N CC(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CC(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O LEMGAKAAUNGWHX-UHFFFAOYSA-N 0.000 description 1
- RFLTUNKOJLSFRI-UHFFFAOYSA-N CC(CC1)CCN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CC(CC1)CCN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O RFLTUNKOJLSFRI-UHFFFAOYSA-N 0.000 description 1
- HMCFXEKTKFEKCT-UHFFFAOYSA-N CC(CCC1)CN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CC(CCC1)CN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O HMCFXEKTKFEKCT-UHFFFAOYSA-N 0.000 description 1
- HSXOJHXRNKVLHL-VURMDHGXSA-N CC(CN(CC1)C(C(C(/C=C\N)=C2C)=CN(C)C2=O)=O)C1N(C)C Chemical compound CC(CN(CC1)C(C(C(/C=C\N)=C2C)=CN(C)C2=O)=O)C1N(C)C HSXOJHXRNKVLHL-VURMDHGXSA-N 0.000 description 1
- VWVDYFBWPFYGNZ-UHFFFAOYSA-N CC(CN(CC1)CCC1NC)c1ccccc1 Chemical compound CC(CN(CC1)CCC1NC)c1ccccc1 VWVDYFBWPFYGNZ-UHFFFAOYSA-N 0.000 description 1
- JAKDWKVKEBOKAO-UHFFFAOYSA-N CC(N(CC1)CCC1C1=NCCC=C1)=O Chemical compound CC(N(CC1)CCC1C1=NCCC=C1)=O JAKDWKVKEBOKAO-UHFFFAOYSA-N 0.000 description 1
- ADKJRMANIGACDE-UHFFFAOYSA-N CC(N(CC1)CCC1[n]1c(cccc2)c2nc1)=O Chemical compound CC(N(CC1)CCC1[n]1c(cccc2)c2nc1)=O ADKJRMANIGACDE-UHFFFAOYSA-N 0.000 description 1
- GWFPELGLVGDRGE-UHFFFAOYSA-N CCCC(N(CC1)CC=C1c1nccnc1)=O Chemical compound CCCC(N(CC1)CC=C1c1nccnc1)=O GWFPELGLVGDRGE-UHFFFAOYSA-N 0.000 description 1
- UGJCAXHVKZMJJA-UHFFFAOYSA-N CCN(CC)C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CCN(CC)C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O UGJCAXHVKZMJJA-UHFFFAOYSA-N 0.000 description 1
- FBVGIYYPPOCZOL-UHFFFAOYSA-N CCS(C)C(N(C)CC1CCN(CC2COCCC2)CC1)=O Chemical compound CCS(C)C(N(C)CC1CCN(CC2COCCC2)CC1)=O FBVGIYYPPOCZOL-UHFFFAOYSA-N 0.000 description 1
- ZEXPBEBJNWJYOD-UHFFFAOYSA-N CCc(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CCc(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O ZEXPBEBJNWJYOD-UHFFFAOYSA-N 0.000 description 1
- BXDBCNHTWWMPOP-UHFFFAOYSA-N CCc1cccc(N(CC2)CCC2N(C)C(C(C2C=CNC22)=CN(C)C2=O)=O)c1 Chemical compound CCc1cccc(N(CC2)CCC2N(C)C(C(C2C=CNC22)=CN(C)C2=O)=O)c1 BXDBCNHTWWMPOP-UHFFFAOYSA-N 0.000 description 1
- JZSMQBUKLWKLAH-UHFFFAOYSA-N CN(C(CC1)CCN1c1nc(C#N)ncc1)C(C(c1c2[nH]cc1)=CN(CC=C)C2O)=O Chemical compound CN(C(CC1)CCN1c1nc(C#N)ncc1)C(C(c1c2[nH]cc1)=CN(CC=C)C2O)=O JZSMQBUKLWKLAH-UHFFFAOYSA-N 0.000 description 1
- MKBQGEGVONDJOL-UHFFFAOYSA-N CN(C(CC1)CCN1c1nc(C(F)(F)F)ccn1)C(C(C1C=CNC11)=CN(CC=C)C1O)=O Chemical compound CN(C(CC1)CCN1c1nc(C(F)(F)F)ccn1)C(C(C1C=CNC11)=CN(CC=C)C1O)=O MKBQGEGVONDJOL-UHFFFAOYSA-N 0.000 description 1
- HPNQBNLYZZQXKT-UHFFFAOYSA-N CN(C(CC1)CCN1c1ncncc1)C(C(c1c2[nH]cc1)=CN(CC=C)C2=O)=O Chemical compound CN(C(CC1)CCN1c1ncncc1)C(C(c1c2[nH]cc1)=CN(CC=C)C2=O)=O HPNQBNLYZZQXKT-UHFFFAOYSA-N 0.000 description 1
- BKNNKEDBPTYNGM-UHFFFAOYSA-N CN(C)C(C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O)=O Chemical compound CN(C)C(C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O)=O BKNNKEDBPTYNGM-UHFFFAOYSA-N 0.000 description 1
- CFXSNMNOGBSDGU-UHFFFAOYSA-N CN(C)C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(CCC1CC1)C2=O)=O Chemical compound CN(C)C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(CCC1CC1)C2=O)=O CFXSNMNOGBSDGU-UHFFFAOYSA-N 0.000 description 1
- RHTIIFADKOEUSR-UHFFFAOYSA-N CN(C)C(N(CC1)CCC1c1ncncc1)=O Chemical compound CN(C)C(N(CC1)CCC1c1ncncc1)=O RHTIIFADKOEUSR-UHFFFAOYSA-N 0.000 description 1
- BWDUSWMVCCCWOD-UHFFFAOYSA-N CN(C1CCCCC1)C(CC1)CCN1C=O Chemical compound CN(C1CCCCC1)C(CC1)CCN1C=O BWDUSWMVCCCWOD-UHFFFAOYSA-N 0.000 description 1
- IYIIMQCNUYRHBO-UHFFFAOYSA-N CN(C1O)C=C(C2OC2N(CC2)CCC2N2CCOCC2)c2c1[nH]cc2 Chemical compound CN(C1O)C=C(C2OC2N(CC2)CCC2N2CCOCC2)c2c1[nH]cc2 IYIIMQCNUYRHBO-UHFFFAOYSA-N 0.000 description 1
- RNYPMKBFHRSMPM-UHFFFAOYSA-N CN(C=C(C(N(CC1)CCC1C#N)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N(CC1)CCC1C#N)=O)c1c2[nH]cc1)C2=O RNYPMKBFHRSMPM-UHFFFAOYSA-N 0.000 description 1
- BXQUMVORFIOMJP-UHFFFAOYSA-N CN(C=C(C(N(CC1)CCC1C(F)(F)F)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N(CC1)CCC1C(F)(F)F)=O)c1c2[nH]cc1)C2=O BXQUMVORFIOMJP-UHFFFAOYSA-N 0.000 description 1
- KFFRKYMJDNFLSJ-UHFFFAOYSA-N CN(C=C(C(N(CC1)CCC1OC)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N(CC1)CCC1OC)=O)c1c2[nH]cc1)C2=O KFFRKYMJDNFLSJ-UHFFFAOYSA-N 0.000 description 1
- MOVIQYNEXLEQEM-UHFFFAOYSA-N CN(C=C(C(N1CCC(CC2N=CC=CC2)CC1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N1CCC(CC2N=CC=CC2)CC1)=O)c1c2[nH]cc1)C2=O MOVIQYNEXLEQEM-UHFFFAOYSA-N 0.000 description 1
- SVPKPAOXAZWQPH-UHFFFAOYSA-N CN(C=C(C(N1CCC(CCc2ccncc2)CC1)O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N1CCC(CCc2ccncc2)CC1)O)c1c2[nH]cc1)C2=O SVPKPAOXAZWQPH-UHFFFAOYSA-N 0.000 description 1
- NQUSIPINLCHYRE-UHFFFAOYSA-N CN(C=C(C(N1CCC(CO)CC1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N1CCC(CO)CC1)=O)c1c2[nH]cc1)C2=O NQUSIPINLCHYRE-UHFFFAOYSA-N 0.000 description 1
- FUDSXSIRXAOABP-UHFFFAOYSA-N CN(C=C(C(N1CCCCC1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N1CCCCC1)=O)c1c2[nH]cc1)C2=O FUDSXSIRXAOABP-UHFFFAOYSA-N 0.000 description 1
- VZDGRRGLSFQPCC-UHFFFAOYSA-N CN(C=C(C1OC1N(CC1)CCC1c1ccccc1)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C1OC1N(CC1)CCC1c1ccccc1)c1c2[nH]cc1)C2=O VZDGRRGLSFQPCC-UHFFFAOYSA-N 0.000 description 1
- DOJJCJLLNUPQSU-UHFFFAOYSA-N CN(CC(CC1)CCN1c1ncncc1)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CN(CC(CC1)CCN1c1ncncc1)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O DOJJCJLLNUPQSU-UHFFFAOYSA-N 0.000 description 1
- OSOZVNXWKSZTGJ-UHFFFAOYSA-N CN(CC1)CCN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O OSOZVNXWKSZTGJ-UHFFFAOYSA-N 0.000 description 1
- TYWQMEBQIZLNKW-UHFFFAOYSA-N Cc(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound Cc(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O TYWQMEBQIZLNKW-UHFFFAOYSA-N 0.000 description 1
- TYELAZUJANXRHV-UHFFFAOYSA-N Cc1cc(NC(C(CN(C)C2=O)c3c2[nH]cc3)=O)ccc1 Chemical compound Cc1cc(NC(C(CN(C)C2=O)c3c2[nH]cc3)=O)ccc1 TYELAZUJANXRHV-UHFFFAOYSA-N 0.000 description 1
- INBAALZXDRSEDW-UHFFFAOYSA-N Cc1ccccc1CN1CCC(CN(C)C=O)CC1 Chemical compound Cc1ccccc1CN1CCC(CN(C)C=O)CC1 INBAALZXDRSEDW-UHFFFAOYSA-N 0.000 description 1
- FHXKOHRPZOJNSQ-UHFFFAOYSA-N O=CN(CC1)CCC1c(cc1)ccc1Cl Chemical compound O=CN(CC1)CCC1c(cc1)ccc1Cl FHXKOHRPZOJNSQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077711P | 2014-11-10 | 2014-11-10 | |
| US62/077,711 | 2014-11-10 | ||
| PCT/US2015/059997 WO2016077375A1 (en) | 2014-11-10 | 2015-11-10 | Bromodomain inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533250A JP2017533250A (ja) | 2017-11-09 |
| JP2017533250A5 true JP2017533250A5 (enExample) | 2018-12-20 |
| JP6639497B2 JP6639497B2 (ja) | 2020-02-05 |
Family
ID=54705827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525079A Expired - Fee Related JP6639497B2 (ja) | 2014-11-10 | 2015-11-10 | ブロモドメインインヒビターおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10258603B2 (enExample) |
| EP (1) | EP3218376B1 (enExample) |
| JP (1) | JP6639497B2 (enExample) |
| CN (1) | CN107108613B (enExample) |
| WO (1) | WO2016077375A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840489B2 (en) | 2013-12-20 | 2017-12-12 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Piperidine carboxamide compound, preparation method, and usage thereof |
| WO2016077375A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| MA40943A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| CN107531692B (zh) | 2015-01-29 | 2020-12-25 | 基因泰克公司 | 治疗化合物及其用途 |
| EP3892272B1 (en) | 2016-04-22 | 2024-07-24 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2018137655A1 (zh) * | 2017-01-25 | 2018-08-02 | 江苏豪森药业集团有限公司 | 吡咯并吡啶类n-氧化衍生物及其制备方法和应用 |
| EP3782995B1 (en) * | 2018-04-20 | 2023-11-22 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Spiro condensed imidazoline-2,4-dione derivatives as histone acetyltransferase inhibitors for the treatment of cancer diseases |
| CN112739690A (zh) * | 2018-07-24 | 2021-04-30 | 埃皮兹姆公司 | 用作smarca2拮抗剂的吡啶-2-酮化合物 |
| EP3986895B1 (en) * | 2019-06-21 | 2023-03-15 | F. Hoffmann-La Roche AG | Egfr inhibitors for the treatment of cancer |
| US11171132B2 (en) * | 2019-10-03 | 2021-11-09 | Globalfoundries U.S. Inc. | Bi-directional breakdown silicon controlled rectifiers |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| JP7746278B2 (ja) | 2020-03-05 | 2025-09-30 | シーフォー セラピューティクス， インコーポレイテッド | Ｂｒｄ９の標的分解のための化合物 |
| WO2022051565A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions |
| TW202237095A (zh) | 2020-12-03 | 2022-10-01 | 德商艾斯巴赫生物有限公司 | Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性 |
| AU2022380725A1 (en) * | 2021-11-03 | 2024-05-23 | Vyne Therapeutics Inc. | Uses of pan bet inhibitors |
| EP4518862A1 (en) | 2022-05-02 | 2025-03-12 | Eisbach Bio GmbH | Use of alc1 inhibitors and synergy with parpi |
| CN119384408A (zh) | 2022-06-16 | 2025-01-28 | 安菲斯塔治疗有限责任公司 | 用于靶向蛋白降解的双功能分子 |
| KR20250087545A (ko) | 2022-09-13 | 2025-06-16 | 암피스타 테라퓨틱스 엘티디 | 표적 단백질 분해를 위한 화합물 |
| GB202300833D0 (en) * | 2023-01-19 | 2023-03-08 | Nrg Therapeutics Ltd | Novel compounds |
| WO2025085564A1 (en) * | 2023-10-16 | 2025-04-24 | Kronos Bio, Inc. | Lysine acetyltransferase inhibitors |
| GB202319256D0 (en) | 2023-12-15 | 2024-01-31 | Amphista Therapeutics Ltd | Novel compounds for targeted protein degradation |
| WO2025191109A1 (en) | 2024-03-13 | 2025-09-18 | Amphista Therapeutics Limited | Combinations comprising brd9 bifunctional compounds and their use in the treatment of cancer |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| EP0772609B1 (en) | 1994-07-21 | 1999-02-24 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE122005000053I2 (de) | 1995-03-30 | 2008-01-17 | Pfizer Prod Inc | Chinazolinderivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US6344459B1 (en) | 1996-04-12 | 2002-02-05 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
| ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| HUP0004286A3 (en) | 1997-11-06 | 2002-01-28 | American Cyanamid Co Madison | Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps |
| HUP0104211A3 (en) | 1998-11-19 | 2003-01-28 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it |
| EP1953147A1 (en) | 2005-11-21 | 2008-08-06 | Japan Tobacco, Inc. | Heterocyclic compound and medicinal application thereof |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US20140094456A1 (en) | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| WO2014125408A2 (en) | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
| CA2904049A1 (en) * | 2013-03-11 | 2014-10-09 | Abbvie Inc. | Fused tetracyclic bromodomain inhibitors |
| AR095266A1 (es) | 2013-03-12 | 2015-09-30 | Abbvie Inc | Inhibidores de bromodominios tetraciclicos |
| CN104211639A (zh) | 2013-06-05 | 2014-12-17 | 中国科学院上海药物研究所 | 一类炔基杂环类化合物及其应用 |
| KR20160018811A (ko) | 2013-06-12 | 2016-02-17 | 비아멧 파마슈티컬즈, 인코포레이티드 | 금속 효소 억제 화합물 |
| HK1224297A1 (zh) | 2013-06-28 | 2017-08-18 | Abbvie Inc. | 布罗莫结构域抑制剂 |
| US20150148372A1 (en) | 2013-11-26 | 2015-05-28 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| NZ725930A (en) | 2014-04-23 | 2023-04-28 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| JP6820254B2 (ja) * | 2014-10-10 | 2021-01-27 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| MA40940A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2016077375A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| CN107531690B (zh) | 2014-11-27 | 2020-11-06 | 基因泰克公司 | 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物 |
| US9695200B2 (en) | 2015-01-23 | 2017-07-04 | Confluence Life Sciences, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
| CN107531692B (zh) | 2015-01-29 | 2020-12-25 | 基因泰克公司 | 治疗化合物及其用途 |
-
2015
- 2015-11-10 WO PCT/US2015/059997 patent/WO2016077375A1/en not_active Ceased
- 2015-11-10 JP JP2017525079A patent/JP6639497B2/ja not_active Expired - Fee Related
- 2015-11-10 CN CN201580072351.6A patent/CN107108613B/zh not_active Expired - Fee Related
- 2015-11-10 EP EP15801563.6A patent/EP3218376B1/en active Active
-
2017
- 2017-05-10 US US15/592,012 patent/US10258603B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533250A5 (enExample) | ||
| JP2019516757A5 (enExample) | ||
| JP2017530176A5 (enExample) | ||
| JP2017533249A5 (enExample) | ||
| JP2019516759A5 (enExample) | ||
| JP2017526696A5 (enExample) | ||
| JP2017537100A5 (enExample) | ||
| JP2018510851A5 (enExample) | ||
| JP2017533248A5 (enExample) | ||
| JP2018501287A5 (enExample) | ||
| JP2017525740A5 (enExample) | ||
| JP2017530984A5 (enExample) | ||
| AU2018226470B2 (en) | Compounds for treatment of cancer | |
| ES2877629T3 (es) | Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
| CN107250149A (zh) | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 | |
| JP2015500209A5 (enExample) | ||
| JP2012526143A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| JP2017510641A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2005526741A5 (enExample) | ||
| WO2013036912A3 (en) | Amido compounds as rorϒtmodulators and uses thereof | |
| WO2017040993A4 (en) | Small molecule inhibitors of dyrk1a and uses thereof | |
| JP2014512404A5 (enExample) |